The global monoclonal antibodies market was worth US$ 186 billion in 2021 and is expected to grow at a CAGR of 12% between 2022 and 2032. The rising prevalence of chronic diseases such as cancer, cardiovascular disease, and others is increasing demand for biologics, which is expected to drive the monoclonal antibodies (mAbs) market. Similarly, increasing applications of mAb therapies for targeted therapies, as well as rising awareness of such therapies among patients and physicians, are expected to contribute significantly to market growth.
Human mAbs modulate effector functions efficiently and are less immunogenic than chimeric or humanised mAbs. These antibodies can be produced in transgenic mice using phage display and hybridoma technologies. As a result of recent advances in genetic engineering technology, the production of fully human mAbs is expected to gain traction in the near future.
Request Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15756
North America held the largest market share of 46.2% in 2021, owing to a well-developed healthcare infrastructure, high patient awareness, and increased cancer research prospects, among other factors. Furthermore, rising government spending on cancer research, as well as the presence of key players such as Pfizer Inc., Amgen, Inc., and Merck & Co., are expected to drive market growth. Rising healthcare spending around the world, increased patient awareness, and the availability of advanced hospital infrastructure in developed countries are all expected to contribute to the segment’s dominance during the forecast period.
Key Takeaways from the Market Study
- In 2021, the global monoclonal antibodies market was worth USD 186 billion.
- During the forecast period of 2022 to 2032, the market is expected to grow at a CAGR of 12%, reaching a total of US$ 647.01 Billion in 2032.
- In 2021, the human source type held the largest share, accounting for 54.07% of the market value.
- In 2022, the North American market for monoclonal antibodies is expected to grow to 46.2%.
- Asia Pacific is expected to grow at the fastest rate during the forecast period.
“Because of the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, applications of mAbs for the treatment of autoimmune diseases are expected to grow at a rapid pace.” comments a Future Market Insights analyst.
Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-15756
Competitive Landscape
As many companies focus their efforts on research and the development of innovative diagnostic techniques through product line expansions, acquisitions, and mergers, the market is expected to become more competitive in the near future. Key players in the Monoclonal Antibodies market areNovartis AG; Pfizer Inc; GlaxoSmithKline plc; Amgen Inc.; Merck & Co., Inc.; Daiichi Sankyo Company, Limited; Abbott Laboratories; AstraZeneca plc; Eli Lilly And Company; Johnson & Johnson Services, Inc. and many more.
- Bristol-Myers Squibb Company received FDA approval in November 2021 for Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer. Patients with squamous or non-squamous disease are eligible for the treatment, regardless of PD-L1 expression. 1 This application was reviewed using the FDA’s Real-Time Oncology Examine (RTOR) pilot programme, which aims to ensure that safe and effective medicines are available to patients as soon as possible.
- Sanofi S.A. and Blackstone Life Sciences formed a partnership in March 2022 to accelerate the development of a subcutaneous formulation of Sarclisa mAb for the treatment of patients with multiple myeloma.
Key players covered in the report include:
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Amgen Inc.
- Merck & Co. Inc.
- Daiichi Sankyo Company Limited
- Abbott Laboratories
Key Segments Profiled in the Monoclonal Antibodies Market Industry Survey
Monoclonal Antibodies Market by Production Type:
- In Vivo
- In Vitro
Monoclonal Antibodies Market by Source Type:
- Murine
- Chimeric
- Humanized
- Human
Monoclonal Antibodies Market by End User:
- Hospitals
- Specialty Centers
- Others
Monoclonal Antibodies Market by Application:
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Neurological Diseases
- Others
Buy Now@ https://www.futuremarketinsights.com/checkout/15756
More Valuable Insights
Future Market Insights’ new offering provides an unbiased analysis of the global monoclonal antibodies market, with historical data from 2016 to 2021 and forecast data from 2022 to 2032.
The study reveals essential insights on the basis of test type (tumor biomarkers tests, imaging, biopsy, liquid biopsy, immunohistochemistry, in situ hybridization), by indication (breast cancer, lung cancer, colorectal cancer, melanoma, blood cancer, prostate cancer, ovarian cancer, stomach cancer, liver cancer and others) and by end-user (hospital associated labs, independent, diagnostic laboratories, diagnostic imaging centers, cancer research institutes and others) and regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).
About the Healthcare at Future Market Insights
The healthcare domain at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs